Nitric oxide donor nitrosorbide potentiates the antitumor effect of doxorubicin against experimental glioblastoma

Alekseeva A.I.

Avtsyn Research Institute of Human Morphology;
Institute of Higher Nervous Activity and Neurophysiology

Kudelkina V.V.

Avtsyn Research Institute of Human Morphology

Kosyreva A.M.

Avtsyn Research Institute of Human Morphology

Drozd S.F.

Burdenko Neurosurgical Center

Gelperina S.E.

Mendeleev National University of Chemical Technology

Pavlova G.V.

Burdenko National Medical Research Center of Neurosurgery

SPIN RSCI: 4633-8339
Scopus AuthorID: 7005650683
ORCID: 0000-0002-6885-6601

Khalansky A.S.

Avtsyn Research Institute of Human Morphology

Nitric oxide donor nitrosorbide potentiates the antitumor effect of doxorubicin against experimental glioblastoma

Authors:

Alekseeva A.I., Kudelkina V.V., Kosyreva A.M., Drozd S.F., Gelperina S.E., Pavlova G.V., Khalansky A.S.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(1): 66‑73

DOI: 10.17116/neiro20228601166

Downloaded: 39

To cite this article:

Alekseeva AI, Kudelkina VV, Kosyreva AM, Drozd SF, Gelperina SE, Pavlova GV, Khalansky AS. Nitric oxide donor nitrosorbide potentiates the antitumor effect of doxorubicin against experimental glioblastoma. Burdenko's Journal of Neurosurgery. 2022;86(1):66‑73. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20228601166

Close metadata

BACKGROUND

Doxorubicin is a well-known antitumor drug that is not employed for chemotherapy of brain tumors. Indeed, doxorubicin does not penetrate across the blood-brain barrier in therapeutic concentrations.

OBJECTIVE

To study the antitumor effect of doxorubicin combined with nitrosorbide on intracranial experimental glioblastoma 101/8 in rats.

MATERIAL AND METHODS

Male Wistar rats (n=86) with intracranial implanted glioblastoma 101/8 received doxorubicin (i.v. 1.5 mg/kg thrice) alone or in combination with nitrosorbide (i.v or orally, 0.5 mg/kg thrice) in 2, 5 and 8 days after implantation. Efficacy was assessed considering survival and brain tumor volume in 14 days after tumor implantation.

RESULTS

Combination of doxorubicin and nitrosorbide significantly increased survival (57% and 155%, respectively) and slowed down tumor growth (16±12 and 8±6 mm³, respectively) compared to doxorubicin alone. Effectiveness of nitrosorbide alone was trivial.

CONCLUSION

Nitric oxide donor nitrosorbide considerably potentiated the antitumor effect of doxorubicin against intracranial 101/8 glioblastoma in rats.

Keywords:

101/8 glioblastoma in rats

nitrosorbide

doxorubicin

P-glycoprotein

Authors:

Alekseeva A.I.

Avtsyn Research Institute of Human Morphology;
Institute of Higher Nervous Activity and Neurophysiology

Kudelkina V.V.

Avtsyn Research Institute of Human Morphology

Kosyreva A.M.

Avtsyn Research Institute of Human Morphology

Drozd S.F.

Burdenko Neurosurgical Center

Gelperina S.E.

Mendeleev National University of Chemical Technology

Pavlova G.V.

Burdenko National Medical Research Center of Neurosurgery

SPIN RSCI: 4633-8339
Scopus AuthorID: 7005650683
ORCID: 0000-0002-6885-6601

Khalansky A.S.

Avtsyn Research Institute of Human Morphology

Received:

26.06.2020

Accepted:

29.11.2021

List of references:

Kobyakov GL, Smolin AV, Bekyashev AKh, Absalyamova OV, Kobyakova EA, Poddubsky AA, Inozemtseva MV. Treatment for recurrent glioblastoma: are there successes? Opukholi golovy i shei. 2014;3:12-21. (In Russ.). https://doi.org/10.17650/2222-1468-2014-0-3-872-878
Da Ros M, Lorio AL, Lucchesi M, Stival A, de Martino M, Sardi L. The use of anthracyclines for therapy of CNS brain tumors. Anti-Cancer Agents in Medicinal Chemistry. 2015;15(6)721-727. https://doi.org/10.2174/1871520615666150407155319
Sardi I, la Marca G, Cardellicchio S, Giunti L, Malvagia S, Genitori L, Massimino M, de Martino M, Giovannini MG. Pharmacological modulation of blood-brain barrier increases permeability of doxorubicin into the rat brain. American Journal of Cancer Research. 2013;3(4):424-432.
Brandsma D, Dieras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P, Jager A, van Linde M, Aftimos P. P08.03. 2B3-101, Glutathione PEGylated liposomal doxorubicin in patients with recurrent high grade gliomas and breast cancer brain metastases. Neuro-Oncology. 2014;16(2):ii1-ii112. https://doi.org/10.1093/neuonc/nou174.191
Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H, Rosenthal MA. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. Journal of Clinical Neuroscience. 2015;22(12):1889-1894. https://doi.org/10.1016/j.jocn.2015.06.005
Korde Choudhari S, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World Journal of Surgical Oncology. 2013;11:118. https://doi.org/10.1186/1477-7819-11-118
Sinhaa BK, Bortner CD, Masona RP, Cannon RE. Nitric oxide reverses drug resistance by inhibiting ATPase activity of pglycoprotein in human multi-drug resistant cancer cells. Biochimica et Biophysica Acta (BBA) — General Subjects. 2018;1862(12):2806-2814. https://doi.org/10.1016/j.bbagen.2018.08.021
Thiel VE, Audus KL. Nitric Oxide and Blood-Brain Barrier Integrity. Antioxidants and Redox Signaling. 2004;3(2):273-278. https://doi.org/10.1089/152308601300185223
Alekseeva AI, Khalansky AS, Fedoseeva VV, Gorelikov PL, Gelperina SE. Potentiating effect of nitric oxide donor on antitumor activity of doxorubicin in glioblastoma-bearing rats. Antibiotiki i khimioterapiia. 2018;63(7-8): 17-21. (In Russ.). https://doi.org/10.24411/0235-2990-2018-00029
Khalansky AS, Kondakova LI. Perevivaemyy shtamm gliomy krysy 101.8. I. Biologicheskaya kharakteristika. Klinicheskaya i eksperimental’naya morfologiya. 2013;8(4):63-68. (In Russ.).
Rukovodstvo po provedeniyu doklinicheskikh issledovanij lekarstvennykh sredstv. Mironov AN, ed. M.: Grif i K; 2013.
Mkhitarov VA, Makarova OV, Fedoseeva VV, Khalansky AS, Mihailova LP, Gelperina SE, Maksimenko OO, Razzhivina VA, Balabanyan VYu. Methodology for estimating the volume of experimental tumors using 3D reconstruction. Klinicheskaya i eksperimental’naya morfologiya. 2015;16(4):42-46. (In Russ.).
Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very Important Pharmacogene Summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and Genomics. 2011;21(3):152-161. https://doi.org/10.1097/FPC.0b013e3283385a1c
Huang Zh, Fu J, Zhang Y. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. Journal of Medicinal Chemistry. 2017;60(18):7617-7635. https://doi.org/10.1021/acs.jmedchem.6b01672
Godínez-Rubí M, Rojas-Mayorquín AE, Ortuño-Sahagún D. Nitric Oxide Donors as Neuroprotective Agents after an Ischemic Stroke-Related Inflammatory Reaction. Oxidative Medicine and Cellular Longevity. 2013;2013:297357. https://doi.org/10.1155/2013/297357
Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. European Journal of Pharmaceutics and Biopharmaceutics. 2010;74(2):157-163. https://doi.org/10.1016/j.ejpb.2009.09.003
Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One. 2011;6(5):e19121. https://doi.org/10.1371/journal.pone.0019121
Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko LT, Korolev AM. Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide. 2003;8(1):59-64. https://doi.org/10.1016/s1089-8603(02)00142-8
Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L, Szabó C, Pacher P. Role of Superoxide, Nitric Oxide, and Peroxynitrite in Doxorubicin-Induced Cell Death in Vivo and in Vitro. American Journal of Physiology. Heart and Circulatory Physiology. 2009;296(5):1466-1483. https://doi.org/10.1152/ajpheart.00795.2008

Close metadata